Evidence map›Paper›PMID 34514762›Full record

Observational studyJBRA assisted reproduction2022

Evaluation of the Anti-Müllerian Hormone and its Association with Embryo Quality in Advanced Reproductive Treatments in a Latin American Population.

Héctor Salvador Godoy Morales, Germán Gabriel Palacios López, Daniel Vieyra Cortés, Griselda Claribel Reyes Torres, Hilda Sanchez Hernández, Miguel Loyo Guiot, Francisco Miguel Rojas Camacho, Gabriela Ayala Montoya, Berenice Flores Maldonado

Abstract readObservational Study
In one paragraph

Observational study in JBRA assisted reproduction, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Héctor Salvador Godoy MoralesHead of Assisted Research and Treatment in Human Reproduction (ART) Reproductive Medicine Unit at Ángeles del Pedregal Hospital, Mexico City, Mexico.
Germán Gabriel Palacios LópezSpecialist in Human Reproductive Medicine and Master in Health Sciences, Mexico City, Mexico.
Daniel Vieyra CortésSpecialist in Human Reproductive Medicine, Mexico City, Mexico.
Griselda Claribel Reyes TorresResident of Human Reproductive Medicine at Ángeles del Pedregal Hospital, Mexico City, Mexico.
Hilda Sanchez HernándezResident of Human Reproductive Medicine at Ángeles del Pedregal Hospital, Mexico City, Mexico.
Miguel Loyo GuiotResident of Human Reproductive Medicine at Ángeles del Pedregal Hospital, Mexico City, Mexico.
Francisco Miguel Rojas CamachoResident of Human Reproductive Medicine at Ángeles del Pedregal Hospital, Mexico City, Mexico.
Gabriela Ayala MontoyaResident of Human Reproductive Medicine at Ángeles del Pedregal Hospital, Mexico City, Mexico.
Berenice Flores MaldonadoResident of Human Reproductive Medicine at Ángeles del Pedregal Hospital, Mexico City, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveSerum anti-Müllerian hormone (AMH) presents a strong positive correlation with quantitative aspects of the ovarian reserve, while its correlation with embryo quality is unclear. This study assessed the association between serum AMH as a marker of ovarian reserve and embryo quality, in women undergoing in vitro fertilization.

methodsThis observational analytical retrospective study included patients seen between 2010 and 2018. In vitro fertilization patients with measured AMH levels were analyzed based on the following parameters: number of retrieved oocytes; number of metaphase II oocytes; embryo quality; and treatment outcome. Statistical analysis was performed using ANOVA, Mann-Whitney U test, linear regression, and Pearson and Spearman correlations.

resultsWe found a positive correlation between AMH levels, number of retrieved oocytes and number of metaphase II oocytes (r 0.649, p=0.000). The numbers of retrieved and metaphase II oocytes were predicted in 42% (R2: 429) of the cases based on AMH levels (p=0.000). Serum AMH levels were not associated with embryo quality on Day 3 (p=0.151); an association was seen between AMH levels and embryo quality on Day 5 (p=0.006). The distribution of AMH levels was the same across patients, regardless of whether they were able to achieve pregnancy (p=0.767).

conclusionsAMH levels correlated with embryo quality on Day 5; no association was found between AMH levels and embryo quality on Day 3 or pregnancy rate. The use of AMH levels to predict embryo quality still requires further studies; therefore, AMH should be used to assess the ovarian reserve only.

Indexed as

Anti-Mullerian HormoneFertilization in VitroFemaleHumansLatin AmericaOocytesPregnancyPregnancy RateRetrospective StudiesAnti-Mullerian Hormoneadvanced reproductive treatmentsanti-Müllerian hormoneembryo qualityovarian reserve

Identifiers

PMID34514762
PMCPMC8769191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.